Cargando…

Bevacizumab as a steroid‐sparing agent during immunotherapy for melanoma brain metastases: A case series

BACKGROUND: Brain metastases are common in advanced melanoma and often necessitate corticosteroids such as dexamethasone to control symptoms and reduce peritumoral edema. Immunotherapy improves survival in metastatic melanoma, but concomitant treatment with corticosteroids may reduce efficacy. Here,...

Descripción completa

Detalles Bibliográficos
Autores principales:	Banks, Patricia D., Lasocki, Arian, Lau, Peter K. H., Sandhu, Shahneen, McArthur, Grant, Shackleton, Mark
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2019
Materias:	Research Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6427059/ https://www.ncbi.nlm.nih.gov/pubmed/30937392 http://dx.doi.org/10.1002/hsr2.115

Ejemplares similares

Melanoma brain metastases that progress on BRAF-MEK inhibitors demonstrate resistance to ipilimumab-nivolumab that is associated with the Innate PD-1 Resistance Signature (IPRES)
por: Lau, Peter Kar Han, et al.
Publicado: (2021)

Improving the diagnosis of radiation necrosis after stereotactic radiosurgery to intracranial metastases with conventional MRI features: a case series
por: Lasocki, Arian, et al.
Publicado: (2022)

Bevacizumab treatment of meningeal melanoma metastases
por: Simonsen, Trude G., et al.
Publicado: (2020)

SUN-127 Diagnostic Challenges Associated with the Rising Incidence of Endocrine Toxicity in the Era of Combination Immunotherapy
por: Galligan, Anna, et al.
Publicado: (2020)

Steroid-sparing agents for the treatment of inflammation in complicated neurocysticercosis
por: Anand, Pria, et al.
Publicado: (2019)

Tolosa–Hunt Syndrome: Long-Term Outcome and Role of Steroid-Sparing Agents
por: Arthur, Anupriya, et al.
Publicado: (2020)

Tocilizumab as a steroid sparing agent for the treatment of Graves' orbitopathy
por: Russell, David J., et al.
Publicado: (2017)

CLIPPERS Responsive to Cladribine as a Durable Steroid-Sparing Agent
por: Thebault, Simon, et al.
Publicado: (2022)

Efficacy of immune checkpoint inhibitors for in-transit melanoma
por: Nan Tie, Emilia, et al.
Publicado: (2020)

Novel combination therapies for BRAF-mutant melanoma
por: McArthur, Grant A
Publicado: (2015)

Extensive necrosis of visceral melanoma metastases after immunotherapy
por: Stoeter, David, et al.
Publicado: (2008)

Characterization of the treatment-naive immune microenvironment in melanoma with BRAF mutation
por: Wang, Minyu, et al.
Publicado: (2022)

Immunoglobulins as steroid sparing agents in chronic relapsing inflammatory optic neuropathy
por: Gonzalez-Granado, Luis I.
Publicado: (2010)

BRAF-MEK inhibitors as steroid-sparing bridge prior to checkpoint blockade therapy in symptomatic intracranial melanoma
por: Khaddour, Karam, et al.
Publicado: (2021)

Immunotherapy as a Turning Point in the Treatment of Melanoma Brain Metastases
por: Fernandes, Gil Nuno Castro
Publicado: (2023)

Combination Therapies to Inhibit the RAF/MEK/ERK Pathway in Melanoma: We are not Done Yet
por: McArthur, Grant A.
Publicado: (2015)

The role of oral methotrexate as a steroid sparing agent in refractory eosinophilic asthma
por: Bilocca, David, et al.
Publicado: (2017)

Tocilizumab in sarcoidosis patients failing steroid sparing therapies and anti-TNF agents
por: Sharp, Michelle, et al.
Publicado: (2019)

1406. Steroid-Sparing Agents to Control Inflammation in Complicated Neurocysticercosis: Three Cases
por: Anand, Pria, et al.
Publicado: (2019)

OR32-06 Opportunistic Assessment of Pituitary Gland with Routine MRI and PET/CT Can Guide in Earlier and Increased Identification of Hypophysitis in Patients Treated with Combination Checkpoint Inhibitors
por: Galligan, Anna, et al.
Publicado: (2020)

Anti-Inflammatory and General Glucocorticoid Physiology in Skeletal Muscles Affected by Duchenne Muscular Dystrophy: Exploration of Steroid-Sparing Agents
por: Herbelet, Sandrine, et al.
Publicado: (2020)

Harnessing the potential of radiation treatment of brain metastases to improve melanoma immunotherapy
por: McNeilly, Corey D, et al.
Publicado: (2015)

Stereotactic Radiosurgery With Concurrent Immunotherapy in Melanoma Brain Metastases Is Feasible and Effective
por: Liermann, Jakob, et al.
Publicado: (2020)

Triple combinations of immunotherapy and targeted therapy in patients with melanoma with brain metastases
por: Rutkowski, Piotr, et al.
Publicado: (2023)

Efficacy of immunotherapy for melanoma brain metastases in patients with concurrent corticosteroid exposure
por: Tringale, Kathryn R, et al.
Publicado: (2023)

Distant intracranial failure in melanoma brain metastases treated with stereotactic radiosurgery in the era of immunotherapy and targeted agents
por: Acharya, Sahaja, et al.
Publicado: (2017)

i-Move, a personalised exercise intervention for patients with advanced melanoma receiving immunotherapy: a randomised feasibility trial protocol
por: Hyatt, Amelia, et al.
Publicado: (2020)

Efficacy of anti-PD-1 therapy in patients with melanoma brain metastases
por: Parakh, Sagun, et al.
Publicado: (2017)

Checkpoint inhibitors in melanoma and early phase development in solid tumors: what’s the future?
por: Ascierto, Paolo A., et al.
Publicado: (2017)

Tissue-resident memory T cells from a metastatic vaginal melanoma patient are tumor-responsive T cells and increase after anti-PD-1 treatment
por: Pizzolla, Angela, et al.
Publicado: (2022)

Targeting oncogenes in advanced melanoma
por: McArthur, GA
Publicado: (2012)

Real world outcomes of combination and timing of immunotherapy with radiotherapy for melanoma with brain metastases
por: Moyers, Justin T., et al.
Publicado: (2021)

Molecular Features of Resected Melanoma Brain Metastases, Clinical Outcomes, and Responses to Immunotherapy
por: Vasudevan, Harish N., et al.
Publicado: (2023)

The Role of Hydroxychloroquine as a Steroid-sparing Agent in the Treatment of Immune Thrombocytopenia: A Review of the Literature
por: Mohammadpour, Fatemeh, et al.
Publicado: (2018)

The Long-Term Use of Methotrexate Monotherapy as a Steroid-Sparing Agent for Patients With Pulmonary Sarcoidosis
por: Baiyasi, Ahmad F, et al.
Publicado: (2021)

Side effects of steroid-sparing agents in patients with bullous pemphigoid and pemphigus: A systematic review
por: Zeng, Faith A.P., et al.
Publicado: (2022)

Steroid sparing effect of omalizumab in seropositive allergic bronchopulmonary aspergillosis
por: Beam, Keith T., et al.
Publicado: (2015)

A Successful Steroid-Sparing Approach in Cronkhite-Canada Syndrome
por: Mao, Eric J., et al.
Publicado: (2019)

Steroid-sparing effects of benralizumab in patients with eosinophilic granulomatosis with polyangiitis
por: Nanzer, Alexandra M., et al.
Publicado: (2020)

Dupilumab as a novel steroid-sparing treatment for hypereosinophilic syndrome
por: Du, Xiaoman, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_s17np964l89kekhj4pdj47v0s0